The rise of Viagra and its impact on the pharmaceutical landscape presents a intricate question for shareholders. While the early sales data were remarkable, the patent has expired, leading to a wave of off-brand alternatives that are reducing earnings. Moreover, the sector is facing challenges related to demographic trends and shifting healthca… Read More